Literature DB >> 10726709

Hypertension and breast cancer risk in a 19-year follow-up study (the DOM cohort). Diagnostic investigation into mammarian cancer.

P H Peeters1, P A van Noord, A W Hoes, J Fracheboud, C H Gimbrère, D E Grobbee.   

Abstract

BACKGROUND: To investigate whether hypertension and the use of anti-hypertensive drugs are associated with breast cancer risk.
METHODS: This was a prospective study of 11, 011 women living in Utrecht, the Netherlands, aged 50-65 years at enrolment in a breast cancer screening project (DOM cohort). Women attended screening rounds between 1974 and 1985 at which blood pressure was measured and information on drug use and breast cancer risk factors was ascertained. Since 1974 (median follow-up time 19 years), information on breast cancer occurrence and death has been registered. Hypertension was defined as a systolic blood pressure > 160 mmHg or a diastolic blood pressure > 95 mmHg or current use of drugs for the indication hypertension. Cox's regression analysis was used to investigate the association between hypertension (treated or untreated) and subsequent breast cancer risk. Analyses were adjusted for age, body mass index, height, parity, familial breast cancer, smoking and oral contraceptive use.
RESULTS: A total of 523 women were diagnosed with breast cancer. Hypertensive women experienced a statistically significant increased breast cancer risk of 23% (age-adjusted hazard ratio (HRa) = 1.23; 95% confidence interval (CI) 1.01 -1.49). After adjustment for all confounders, the increase was 14% (HR = 1.14; 95% CI 0.93-1.40). The decline in risk was mainly attributable to the effect of BMI. The risk was similar in treated (HR = 1.22; 95% CI 0.91-1.63) and untreated hypertensive women (HR = 1.13; 95% CI 0.91-1.40).
CONCLUSION: These results do not support an association between hypertension and breast cancer, and if there is a link, it is likely to be positive and relatively small in size (+14%). This relation, if present, is not attributable to anti-hypertensive drugs, since the relation is also present in non-drug users.

Entities:  

Mesh:

Year:  2000        PMID: 10726709     DOI: 10.1097/00004872-200018030-00002

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  17 in total

1.  A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer.

Authors:  Geoffrey C Kabat; Mimi Kim; Rowan T Chlebowski; Janu Khandekar; Marcia G Ko; Anne McTiernan; Marian L Neuhouser; Donna R Parker; James M Shikany; Marcia L Stefanick; Cynthia A Thomson; Thomas E Rohan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-30       Impact factor: 4.254

2.  Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort.

Authors:  Joan A Largent; Leslie Bernstein; Pamela L Horn-Ross; Sarah F Marshall; Susan Neuhausen; Peggy Reynolds; Giske Ursin; Jason A Zell; Argyrios Ziogas; Hoda Anton-Culver
Journal:  Cancer Causes Control       Date:  2010-06-06       Impact factor: 2.506

Review 3.  Metabolic syndrome in breast cancer.

Authors:  Víctor Manuel Vargas-Hernández; Vm Vargas-Aguilar; Mario Adanm Moreno-Eutimio; Gustavo Acosta-Altamirano; Jm Tovar-Rodriguez
Journal:  Gland Surg       Date:  2013-05

4.  The Hypertension Related Gene G-Protein Coupled Receptor Kinase 4 Contributes to Breast Cancer Proliferation.

Authors:  Wei Yue; Hanh T Tran; Ji-Ping Wang; Katherine Schiermeyer; John J Gildea; Peng Xu; Robin A Felder
Journal:  Breast Cancer (Auckl)       Date:  2021-05-20

5.  Metabolic syndrome and triple-negative breast cancer: a new paradigm.

Authors:  Andrew A Davis; Virginia G Kaklamani
Journal:  Int J Breast Cancer       Date:  2011-10-15

Review 6.  Cancer Progress and Priorities: Breast Cancer.

Authors:  Serena C Houghton; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-05       Impact factor: 4.090

7.  Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.

Authors:  Ying-Fang Sun; Jyh-Der Leu; Su-Mei Chen; I-Feng Lin; Yi-Jang Lee
Journal:  BMC Cancer       Date:  2009-01-13       Impact factor: 4.430

8.  Combined effects of obesity and type 2 diabetes contribute to increased breast cancer risk in premenopausal women.

Authors:  Majed S Alokail; Nasser M Al-Daghri; Omar S Al-Attas; Tajamul Hussain
Journal:  Cardiovasc Diabetol       Date:  2009-06-23       Impact factor: 9.951

Review 9.  A narrative review on the interaction between genes and the treatment of hypertension and breast cancer.

Authors:  Wenjuan Wang; Qingjian He; Haodong Zhang; Chenchen Zhuang; Qiongying Wang; Caie Li; Runmin Sun; Xin Fan; Jing Yu
Journal:  Ann Transl Med       Date:  2021-05

10.  Metabolic syndrome biomarkers and early breast cancer in Saudi women: evidence for the presence of a systemic stress response and/or a pre-existing metabolic syndrome-related neoplasia risk?

Authors:  Majed S Alokail; Nasser Al-Daghri; Amal Abdulkareem; Hossam M Draz; Sobhy M Yakout; Abdullah M Alnaami; Shaun Sabico; Amal M Alenad; George P Chrousos
Journal:  BMC Cancer       Date:  2013-02-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.